Edgewise Therapeutics, Inc.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision small molecule medicines for severe neuromuscular and cardiac disorders. The company utilizes a proprietary, muscle-focused drug discovery platform that evaluates integrated muscle function in whole organ extracts. Its pipeline features lead candidate sevasemten, an orally administered fast myofiber myosin inhibitor in late-stage clinical trials for Becker muscular dystrophy and Duchenne muscular dystrophy. Edgewise is also developing cardiac sarcomere modulators, including clinical-stage candidate EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure with preserved ejection fraction, along with preclinical cardiometabolic programs. Its intended customer base comprises patients affected by rare, debilitating skeletal and cardiac muscle conditions with limited or no approved therapies.

The company retains global development and commercialization rights to all its programs and plans to establish an internal commercial organization within the United States while evaluating collaborations globally. The provided excerpt contains no information regarding the company's founding year, website, or headquarters location.

Summary of the business section of Edgewise Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 146 full-time employees.”